Cluster headache

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Ref ID: Dousset et al. 2009[232] **Study design:** Validation study (cross-sectional) **Setting:** Outpatients headache clinic, France	**Patient group:** People aged >15 with cluster headache or migraine **Inclusion criteria:** Age >15 years, good knowledge of French, an history of episodic or chronic cluster headache or migraine with or without aura for over a year, an history of at least 2 active cluster periods for patients with episodic cluster headache. All diagnoses were made buy one of 3 headache specialists according to 2004 IHS criteria. **Exclusion criteria:** Possible organic causes of headache were excluded through a general and a neurological examination and if needed complementary exams. **All patients** **N**: 96 **Age mean (SD):** 41.3 (12.5) **F/M:** 54/42 **Drop outs**: 0	**Group 1 – Cluster headache screening questionnaire** Based on 3 most prevalent criteria of ICHD-II for cluster headache: (i) Strictly unilaterality of pain; (ii) Attack duration ≤180 minutes if untreated; (iii) Ipsilateral conjunctival injection, and/or lacrimation. The questionnaire was formed so that they could be quickly filled out and easily understood. At the end of the visit, the nurse of the headache centre explained the objective study and the patients filled the questionnaire out unaided. **Group 2 – ICHD II** Diagnosis made by the headache specialist based on the ICHD-II criteria. This included a medical history and examination. The specialist completed a symptom checklist based on IHS criteria and assigned a clinical diagnosis of migraine, cluster headache or probably cluster headache.	**Sensitivity (%)**	**All 3 questions:** 78.4 **Q 1:** 94.6 **Q2:** 91.1 **Q3:** 89.2 **Q2+3:** 81.1 **Q 1+2:** 86.5 **Q1+3:** 86.5	**Funding:** NR **Limitations:** Original data not reported. Does not specifically say that results were interpreted blind to the other test results – but different assessors completed each. **2x2 table completed:** No
			Specificity (%)	**All 3 questions:** 100 **Q 1:** 44.1 **Q2:** 91.4 **Q3:** 82.5 **Q2+3:** 100 **Q 1+2:** 94.9 **Q1+3:** 88.1	
			Positive predictive value (%)	**All 3 questions:** 100 **Q 1:** 51.5 **Q2:** 87.2 **Q3:** 76.7 **Q2+3:** 100 **Q 1+2:** 91.4 **Q1+3:** 82.1	
			Negative predictive value (%)	**All 3 questions:** 88.1 **Q 1**: 92.9 **Q2:** 94.6 **Q3:** 92.2 **Q2+3**: 89.4 **Q 1+2**: 91.8 **Q1+3:** 91.2	

Abbreviations: NR=not reported, NA=not applicable, M/F=male/female, N=total number of patients randomised, SD=Standard deviation, SE=Standard error, CI=Confidence interval, ICHD II=2nd edition of the International Classification of Headache Disorders

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Ref ID: Torelli et al 2005[794] **Study design:** Validation study **Setting:** Outpatients headache centre, Italy	**Patient group:** Aged over 14 with migraine, tension type headache or cluster headache **Inclusion criteria:** Age 14 years; Good knowledge of Italian; A history of migraine with or without aura, episodic or chronic tension type headache, or chronic cluster headache for over a year; and a history of at least two active cluster periods for patients with episodic cluster headache. **Exclusion criteria:** Possible organic causes of headache were excluded through a general and a neurological examination and, if needed, through instrumental tests. **All patients** **N**: 71 **Age (mean):** 37.5 (15.1) **F/M:** 32/39 (45.1/54.9%) **Drop outs**: 0	**Group 1 – Cluster headache screening questionnaire** Consisted of 16 questions to be answered as 'yes' 'no or 'don't know'. Full questionnaire is available in study. It was designed to be self-administered, easily understood and quick to fill out. At the end of their visit, a diagnosis-blind neurologist explained the objective of the study and they were asked to fill out the questionnaires unaided. **Group 2 – IHS criteria** Initially the 1988 IHS criteria were used, however the second edition (the ICHD-II) was publicised while the study was under-way. All diagnoses established according to 1988 criteria were reviewed applying the 2004 criteria.	**Sensitivity**	**Excrutiating pain:** 100 **Unilaterality:** 100 **Location of pain:** 100 **Conjunctival injection:** 63.3 **Lacrimation**: 80.0 **Nasal congestion:** 63.3 **Rhinorrhea:** 70.0 **Restlessness:** 90.0 **Duration of attacks:** 100 **Frequency of attacks**: 73.3 **Attacks for at least 7 days:** 96.7 **Attacks at fixed hours:** 63.3 **Night attacks:** 63.3 **Remission periods:** 56.7 **Use of preventive treatment:** 66.7	**Funding:** Glaxo Smith Klein **Limitations:** Original data not reported. **Additional outcomes**: Diagnostic outcomes for episodic cluster headache and chronic cluster headache. This seems to be a post-hoc analysis. Not included here. **Notes:** Full questionnaire available in publication **2x2 table completed:** No
			Specificity	**Excrutiating pain:** 34.1 **Unilaterality:** 61.0 **Location of pain:** 58.5 **Conjunctival injection:** 90.2 **Lacrimation**: 75.6 **Nasal congestion:** 90.2 **Rhinorrhea:** 90.2 **Restlessness:** 92.7 **Duration of attacks:** 90.2 **Frequency of attacks**: 73.2 **Attacks for at least 7 days:** 68.3 **Attacks at fixed hours:** 78.0 **Night attacks:** 78.0 **Remission periods:** 95.1 **Use of preventive treatment:** 97.6	

			Positive predictive value	**Excrutiating pain:** 52.6 **Unilaterality:** 65.2 **Location of pain:** 63.8 **Conjunctival injection:** 82.6 **Lacrimation**: 70.6 **Nasal congestion:** 82.6 **Rhinorrhea:** 84.0 **Restlessness:** 90.0 **Duration of attacks:** 88.2 **Frequency of attacks**: 66.7 **Attacks for at least 7 days:** 69.0 **Attacks at fixed hours:** 67.9 **Night attacks:** 67.9 **Remission periods:** 89.5 **Use of preventive treatment:** 95.2	
			Negative predictive value	**Excrutiating pain:** 100 **Unilaterality:** 100 **Location of pain:** 100 **Conjunctival injection:** 77.1 **Lacrimation**: 83.8 **Nasal congestion:** 77.1 **Rhinorrhea:** 80.4 **Restlessness:** 92.7 **Duration of attacks:** 100 **Frequency of attacks**: 78.9 **Attacks for at least 7 days:** 96.6 **Attacks at fixed hours:** 74.4 **Night attacks:** 74.4 **Remission periods:** 75.0 **Use of preventive treatment:** 80.0	

Abbreviations: NR=not reported, NA=not applicable, M/F=male/female, N=total number of patients randomised, SD=Standard deviation, SE=Standard error, CI=Confidence interval, ICHD II=2nd edition of the International Classification of Headache Disorders